Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open, Controlled Study to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals' Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With Either Fluarix™ or the Adjuvanted Vaccine.

NCT00386113 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00386113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00386113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open, Controlled Study to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals' Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With Either Fluarix™ or the Adjuvanted Vaccine.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
October 16, 2006
Completion date
November 14, 2006
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza